Related Experiment Videos
[Which patients are (not) included in the DMP diabetes programme?]
S Dunkelberg1, D Zingel, A Noack
1Institut für Allgemeinmedizin, Universitätsklinikum Hamburg-Eppendorf, Hamburg. dunkelbe@uke.uni-hamburg.de
Summary
Patients in the type 2 diabetes mellitus disease management programme (DMP) and those not enrolled showed similar HbA1c levels. Enrolled patients were younger with better compliance, suggesting potential selection biases in the DMP.
Area of Science:
- Clinical Medicine
- Endocrinology
- Public Health
Background:
- The disease management programme for diabetes mellitus type 2 (DMP) is widely adopted by general practitioners.
- Understanding patient selection criteria and outcomes for DMP participants versus non-participants is crucial for optimizing diabetes care.
- Investigating the reasons behind patient inclusion or exclusion from the DMP can reveal insights into program effectiveness and potential disparities.
Purpose of the Study:
- To compare the characteristics and glycemic control (HbA1c) of type 2 diabetes patients enrolled in a DMP versus those not enrolled.
- To explore the factors influencing general practitioners' decisions in selecting patients for the DMP.
- To evaluate the hypothesis that non-participants have worse glycemic control than DMP participants.
Main Methods:
- A study involving 10 general practitioners in Hamburg, Germany.
- Random selection of 10 DMP participants and 10 non-participants from each GP's patient list.
- Documentation of HbA1c, insulin therapy, comorbidities, language skills, and GP-assessed compliance and selection rationale.
Main Results:
- The primary hypothesis was not confirmed; both groups exhibited similar HbA1c levels (7.0% in DMP, 7.3% in non-DMP).
- DMP participants were significantly younger and demonstrated better compliance compared to non-participants.
- In patients under 70, DMP participants showed a trend towards better HbA1c and more frequent insulin use, though not statistically significant.
Conclusions:
- Some patients may be excluded from the DMP for valid reasons, while others might be included despite already having good metabolic control.
- Further investigation is needed to determine the extent to which patients with good metabolic status are included in the DMP.
- The study raises questions about whether patients with poor compliance, who could potentially benefit, are being excluded from the DMP.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetes Mellitus: Introduction
Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...